Bedrijfsoverzicht
Talphera, Inc. is a specialty pharmaceutical entity dedicated to the research, development, and commercialization of therapeutic agents specifically designed for application within medically supervised environments. The company operates within the broader Healthcare sector, specifically functioning inside the niche industry of Drug Manufacturers - Specialty & Generic, which focuses on producing non-branded or specialized medications for specific therapeutic areas. As of the latest available data, Talphera carries a market capitalization of $38.07M, reports annual revenue of $28,000, and maintains a workforce consisting of 12 employees. These valuation and operational metrics indicate that Talphera is a micro-cap entity with extremely limited revenue generation relative to its market capitalization, suggesting a business model heavily reliant on future asset realization rather than current cash flow operations. The disparity between the substantial market cap of $38.07M and the minimal revenue of $28,000 highlights that the company's valuation is primarily driven by its pipeline assets, such as its lead product candidate Niyad, rather than established commercial sales performance.
Financiële gezondheid
Talphera reports a trailing twelve-month revenue of $28,000, which contrasts sharply with a net income loss of $-14,363,000, revealing a cost structure where expenses significantly exceed all income generation. While the EBITDA metric is currently unavailable, the net income figure demonstrates that operating costs and research expenditures are consuming the entire revenue base. The company's free cash flow stands at $-6,531,500, indicating a net cash outflow that severely limits financial flexibility and necessitates reliance on existing cash reserves or external capital markets to fund operations. Regarding profitability margins, Talphera exhibits a gross margin of 0.0%, an operating margin of -48157.1%, and a profit margin of 0.0%, all of which signify that the company has not yet achieved commercial profitability and is operating at a significant loss relative to sales. In terms of balance sheet leverage, Talphera holds $20.38M in cash against $6.50M in debt, resulting in a debt-to-equity ratio of 38.15, which suggests a highly leveraged position given the negative equity implied by the losses. Despite the high debt-to-equity ratio, the current ratio is reported at 5.49, indicating that the company possesses substantial liquid assets relative to its short-term liabilities, providing a buffer against immediate liquidity pressures. Furthermore, the return on equity is -114.7% and the return on assets is -35.1%, metrics that collectively reveal that management has not yet been effective at generating positive returns on the capital invested in the business.
Waarderingsbeoordeling
The valuation multiples for Talphera show a trailing P/E ratio of N/A due to negative earnings, while the forward P/E is calculated at -2.72, implying that the market expects earnings to remain negative or that valuation is based on theoretical future profitability rather than historical performance. The price-to-book ratio is 2.20, which indicates that the market is pricing the company at more than double its book value, suggesting a premium placed on the company's intangible assets and pipeline potential despite current financial losses. Alternative valuation metrics include a price-to-sales ratio of 1359.57 and an EV/EBITDA of N/A, figures that suggest the market is valuing Talphera almost entirely on the speculative value of its drug candidates rather than revenue or earnings power. The stock has traded between a 52-week high of $1.57 and a 52-week low of $0.38, and without a specific current price, the valuation range reflects high volatility typical of pre-revenue biotech firms. The beta value is 0.56, which indicates that the stock's price volatility is lower than that of the broader market, suggesting that Talphera's share price is less sensitive to general market fluctuations compared to large-cap equities.
Growth & Income
Talphera reports a revenue growth of N/A and earnings growth of N/A, meaning that there is no year-over-year data available to determine if earnings are growing faster or slower than revenue. As the company does not currently pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, which confirms that all earnings are retained within the company to fund ongoing research and development efforts rather than being distributed to shareholders. Since Talphera is not a dividend payer, the company's strategy relies on reinvesting its limited financial resources and cash reserves into growing its pipeline and achieving commercial milestones for its lead product candidate Niyad. The overall growth and income profile for Talphera is characterized by a complete lack of current income distribution and undefined historical growth rates, positioning the asset as a pure-play speculative investment dependent on future clinical or commercial success.